<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39389778</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1936-959X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>AJNR. American journal of neuroradiology</Title><ISOAbbreviation>AJNR Am J Neuroradiol</ISOAbbreviation></Journal><ArticleTitle>Macro- and Microstructural White Matter Differences in Neurologic Postacute Sequelae of SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3174/ajnr.A8481</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Neuropsychiatric complications of SARS-CoV-2 infection, also known as neurologic postacute sequelae of SARS-CoV-2 infection (NeuroPASC), affect 10%-60% of infected individuals. There is growing evidence that NeuroPASC is a multi system immune dysregulation disease affecting the brain. The behavioral manifestations of NeuroPASC, such as impaired processing speed, executive function, memory retrieval, and sustained attention, suggest widespread WM involvement. Although previous work has documented WM damage following acute SARS-CoV-2 infection, its involvement in NeuroPASC is less clear. We hypothesized that macrostructural and microstructural WM differences in NeuroPASC participants would accompany cognitive and immune system differences.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In a cross-sectional study, we screened a total of 159 potential participants and enrolled 72 participants, with 41 asymptomatic controls (NoCOVID) and 31 NeuroPASC participants matched for age, sex, and education. Exclusion criteria included neurologic disorders unrelated to SARS-CoV-2 infection. Assessments included clinical symptom questionnaires, psychometric tests, brain MRI measures, and peripheral cytokine levels. Statistical modeling included separate multivariable regression analyses of GM/WM/CSF volume, WM microstructure, cognitive, and cytokine concentration between-group differences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NeuroPASC participants had larger cerebral WM volume than NoCOVID controls (β = 0.229; 95% CI: 0.017-0.441; <i>t</i> = 2.16; <i>P</i> = .035). The most pronounced effects were in the prefrontal and anterior temporal WM. NeuroPASC participants also exhibited higher WM mean kurtosis, consistent with ongoing neuroinflammation. NeuroPASC participants had more self-reported symptoms, including headache, and lower performance on measures of attention, concentration, verbal learning, and processing speed. A multivariate profile analysis of the cytokine panel showed different group cytokine profiles (Wald-type-statistic = 44.6, <i>P</i> = .046), with interferon (IFN)-λ1 and IFN-λ2/3 levels higher in the NeuroPASC group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NeuroPASC participants reported symptoms of lower concentration, higher fatigue, and impaired cognition compatible with WM syndrome. Psychometric testing confirmed these findings. NeuroPASC participants exhibited larger cerebral WM volume and higher WM mean kurtosis than NoCOVID controls. These findings suggest that immune dysregulation could influence WM properties to produce WM volume increases and consequent cognitive effects and headaches. Further work will be needed to establish mechanistic links among these variables.</AbstractText><CopyrightInformation>© 2024 by American Journal of Neuroradiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0002-9483-1117</Identifier><AffiliationInfo><Affiliation>From the Department of Diagnostic Radiology &amp; Nuclear Medicine (E.E.O., N.R., T.A.Z.), University of Maryland School of Medicine, Baltimore, Maryland erin.oconnor@umm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno-Goncalves</LastName><ForeName>Rosangela</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics (R.S.-G.), University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rednam</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Diagnostic Radiology &amp; Nuclear Medicine (E.E.O., N.R., T.A.Z.), University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lantern Lab (R.O.), Fulton, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rock</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2250-5926</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology (P.R.), University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Andrea R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Medicine (A.R.L.), Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeffiro</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>From the Department of Diagnostic Radiology &amp; Nuclear Medicine (E.E.O., N.R., T.A.Z.), University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AJNR Am J Neuroradiol</MedlineTA><NlmUniqueID>8003708</NlmUniqueID><ISSNLinking>0195-6108</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39389778</ArticleId><ArticleId IdType="doi">10.3174/ajnr.A8481</ArticleId><ArticleId IdType="pii">ajnr.A8481</ArticleId></ArticleIdList></PubmedData></PubmedArticle>